Article
Oncology
Nicole L. L. Edmonds, Sarah E. Gradecki, Priya Katyal, Kevin T. Lynch, Anne M. Stowman, Alejandro A. Gru, Victor H. Engelhard, Craig L. Slingluff Jr, Ileana S. S. Mauldin
Summary: TLS in primary DM differs from TLS in metastatic NDMM in terms of location and T and B-cell density and proliferation. TLS in primary DM may be more immunologically active and have enhanced immune cell trafficking between tumor and TLS compared to NDMM.
Review
Oncology
Daniele Fanale, Alessandra Dimino, Erika Pedone, Chiara Brando, Lidia Rita Corsini, Clarissa Filorizzo, Alessia Fiorino, Maria Chiara Lisanti, Luigi Magrin, Ugo Randazzo, Tancredi Didier Bazan Russo, Antonio Russo, Viviana Bazan
Summary: In this review, the prognostic and predictive role of tumor-infiltrating lymphocytes (TILs) in ovarian cancer (OC) is discussed. Despite the immunogenic potential of OC, immunotherapy has not yielded expected results. Understanding factors influencing infiltration and the crosstalk between cancer and immune cells in the tumor microenvironment (TME) is crucial for unraveling heterogeneity in clinical outcomes. TILs have been recognized as clinically relevant markers for improved survival in OC, and may help identify OC patients who may benefit from immunotherapy.
Article
Biochemistry & Molecular Biology
Marco Pio La Manna, Diana Di Liberto, Marianna Lo Pizzo, Leila Mohammadnezhad, Mojtaba Shekarkar Azgomi, Vincenzo Salamone, Valeria Cancila, Davide Vacca, Costanza Dieli, Rosario Maugeri, Lara Brunasso, Domenico Gerardo Iacopino, Francesco Dieli, Nadia Caccamo
Summary: This study aimed to investigate the role of tissue-resident memory T cells (TRM) in the glioma tumor microenvironment. The findings showed an increased presence of CD8(+) TRM cells in gliomas, which were positively correlated with tumor-infiltrating lymphocytes (TILs) and associated with better survival outcomes. High expression of the gene coding for the integrin CD103 and high CD8(+) TILs abundance were associated with prolonged survival in glioma patients.
Article
Immunology
Haijun Tang, Shangyu Liu, Xiaoting Luo, Yu Sun, Xiangde Li, Kai Luo, Shijie Liao, Feicui Li, Jiming Liang, Xinli Zhan, Qingjun Wei, Yun Liu, Maolin He
Summary: This study developed a new molecular signature based on TILs marker genes, which is very effective in predicting OS prognosis and immunotherapy response.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Natalia Di Ianni, Silvia Musio, Serena Pellegatta
Summary: Glioblastoma metabolism is flexible and adaptable to adverse conditions, with altered lipid metabolism also playing a role in tumor progression. Immunosuppressive microenvironment of GBM involves MDSCs as allies of tumor cells, and there is increasing evidence of interconnection between GBM and MDSC metabolic pathways. Understanding the metabolic programs of GBM and MDSCs is important for improving treatment modalities, including immunotherapeutic strategies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Immunology
Ming Zheng, Yi-Ming Li, Zhen-Yu Liu, Xin Zhang, Yinghui Zhou, Jian-Li Jiang, Ping Zhu, Xiang-Min Yang, Juan Tang, Zhi-Nan Chen
Summary: Immunotherapy targeting tumor-infiltrating lymphocytes has shown promising potential as a treatment for various cancers, but its efficacy varies across different cancer types and patients. The distribution of TIL-T and TIL-B cells and their interactions with the tumor microenvironment play a crucial role in determining the clinical outcomes. Understanding the prognostic significance of these factors can have important implications for cancer immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Samantha M. Fix, Marie-Andree Forget, Donastas Sakellariou-Thompson, Yunfei Wang, Tamara M. Griffiths, Minjung Lee, Cara L. Haymaker, Ana Lucia Dominguez, Rafet Basar, Christopher Reyes, Sanjay Kumar, Larissa A. Meyer, Patrick Hwu, Chantale Bernatchez, Amir A. Jazaeri
Summary: In this study, we optimized CRISPR/Cas9-mediated knockout of TGF-beta receptor 2 (TGFBR2) in patient-derived ovarian cancer TIL. TGFBR2 knockout TIL showed resistance to immunosuppression and improved cytotoxicity. This lays the groundwork for clinical translation of CRISPR-modified TIL for the treatment of ovarian cancer and other solid cancers.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Cell Biology
Roberto Tamma, Giuseppe Ingravallo, Tiziana Annese, Antonio d'Amati, Loredana Lorusso, Domenico Ribatti
Summary: In this study, we analyzed biopsy specimens from adult patients with IDH1 wild type GBM and found that there was a significant increase in the number of total and M2 type macrophages, CD4(+)- and CD8(+)-lymphocytes, and CD34(+) microvessels in the tumor area compared to the healthy surrounding tissue. We also confirmed previous findings that there were higher numbers of p53 and BCL6(+) cells in the tumor area, with a positive correlation between BCL6 and CD34(+) microvessels. These results suggest that microenvironment components play an important role in GBM progression and could potentially be targeted for new therapies.
Article
Biochemistry & Molecular Biology
Claire Y. Li, Hyeung Ju Park, Jinyeon Shin, Jung Eun Baik, Babak J. Mehrara, Raghu P. Kataru
Summary: This study suggests that lymphatic endothelial cells (LECs) can act as immunosuppressive cells in the tumor microenvironment (TME) in an MHC-II dependent manner. LECs in the TME increase MHC-II expression and co-inhibitory signals, suppressing the immune response. This finding highlights the importance of understanding the role of LECs in tumor immunity and opens up new avenues for therapeutic interventions.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, Research & Experimental
Haitang Yang, Sabina Berezowska, Patrick Dorn, Philipp Zens, Peiru Chen, Ren-Wang Peng, Thomas M. Marti, Gregor J. Kocher, Ralph A. Schmid, Sean R. R. Hall
Summary: This study investigates the relationship between the tumor microenvironment (TME) and tumor-infiltrating lymphocytes (TILs) in malignant pleural mesothelioma (MPM). The results suggest that targeting the TME can potentially redirect the fate of TILs and restore anti-tumor immunity in MPM.
Article
Oncology
Veronica Finisguerra, Tereza Dvorakova, Matteo Formenti, Pierre Van Meerbeeck, Lionel Mignion, Bernard Gallez, Benoit J. van den Eynde
Summary: Despite limitations in certain tumor types and patients, immunotherapies have achieved revolutionary success in cancer treatment. However, the efficacy of immunotherapies is dependent on the viability and functionality of tumor antigen-specific CD8 T cells within the immunosuppressive tumor microenvironment, where oxygen levels are often low. This study reveals that the antidiabetic drug metformin can improve CD8 T cell fitness in hypoxia, increasing their proliferation and cytokine production, and enhancing their infiltration and survival in hypoxic tumor areas. This presents a promising strategy to overcome resistance to immunotherapy in hypoxic and immunosuppressive tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Tyler MacNeil, Ioannis A. Vathiotis, Saba Shafi, Thazin Nwe Aung, Jon Zugazagoitia, Aaron M. Gruver, Kyla Driscoll, David L. Rimm
Summary: Pancreatic cancer, characterized by a cold tumor microenvironment and limited immunogenicity, presents challenges for immunotherapy. CD8 and FAP show independent predictive value for progression-free and overall survival in PDAC patients. CD200 exhibits heterogeneous expression in PDAC patients, while CD8 and FAP have potential clinical utility.
Article
Oncology
Xinyue Li, Jing Yang
Summary: This study investigated the relationship between tumor deposits and clinicopathological characteristics, tumor-infiltrating lymphocytes, and prognosis in gastric cancer. The results showed a significant association between tumor deposits and various characteristics and prognosis of gastric cancer, with patients having more than 4 tumor deposits having a worse prognosis.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2022)
Review
Oncology
Yueshui Zhao, Jian Deng, Shuangfeng Rao, Sipeng Guo, Jing Shen, Fukuan Du, Xu Wu, Yu Chen, Mingxing Li, Meijuan Chen, Xiaobing Li, Wanping Li, Li Gu, Yuhong Sun, Zhuo Zhang, Qinglian Wen, Zhangang Xiao, Jing Li
Summary: Cell-based immunotherapy, especially tumor-infiltrating lymphocytes (TILs) therapy, has emerged as a powerful strategy in solid cancer treatment. This review summarizes the current strategies and challenges in TIL generation, and discusses the clinical trials where TIL therapy is used independently or in combination with other therapies for solid tumor treatment. The limitations, future potential, and directions of TIL therapy for solid tumors are also discussed.
Article
Oncology
Jose Manuel Casanova, Jani-Sofia Almeida, John David Reith, Luana Madalena Sousa, Ruben Fonseca, Paulo Freitas-Tavares, Manuel Santos-Rosa, Paulo Rodrigues-Santos
Summary: Osteosarcoma is a common high-grade primary bone tumor that mainly affects young adults. The presence of tumor-infiltrating CD4+ cells is protective for patients, while CD8+ cells have a significant impact on overall survival and progression-free survival. There is a strong association between tumor-infiltrating CD4+ cells and CD44s expression in tumor samples, highlighting the importance of considering TIL and tumor markers for improving OST treatment.
Article
Clinical Neurology
Maria Diaz, Jasmin Jo, Mark Smolkin, Sarah Jane Ratcliffe, David Schiff
Summary: The study found that patients with lower-grade gliomas have a higher VTE risk, which is decreased in the presence of an IDH mutation. The incidence of VTE in glioblastoma patients is not affected by MGMT promoter methylation status.
Article
Oncology
Jasmin Jo, Joseph Donahue, Guneet Sarai, Gina Petroni, David Schiff
Summary: This study aimed to assess the risk of intracranial hemorrhage (ICH) in high-grade glioma (HGG) patients with venous thromboembolism (VTE) on low molecular weight heparin (LMWH). The retrospective matched cohort study found that therapeutic LMWH is not associated with a substantially increased risk of ICH in HGG patients, and the median survival was similar among all three cohorts.
Review
Oncology
Maria Diaz, Jasmin Jo
Summary: Brain tumor patients have a higher risk of VTE, and recent studies have identified new risk factors and molecular mechanisms associated with VTE in these patients. Anticoagulation is necessary for VTE treatment in brain tumor patients, and DOACs may be a feasible option.
CURRENT ONCOLOGY REPORTS
(2022)
Review
Oncology
Jasmin Jo, David Schiff
Summary: Treatment recommendations for grade 3 gliomas depend on their histopathologic and molecular phenotype. The current treatments involve surgery, radiation therapy, and chemotherapy. The addition of temozolomide after radiation therapy improves outcomes for non-codeleted grade 3 IDH mutant astrocytoma. For codeleted oligodendroglioma, the recommended treatment includes procarbazine, CCNU, and vincristine regimen. Novel agents targeting IDH mutation and its metabolic effects are being investigated to further improve patient outcomes.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2022)
Article
Clinical Neurology
Jasmin Jo, Kathryn Nevel, Ryan Sutyla, Mark Smolkin, M. Beatriz Lopes, David Schiff
Summary: Seizures are common among patients with low-grade glioma (LGG), with no significant differences in preoperative or postoperative seizure rates by WHO 2016 classification. Male patients have a higher seizure incidence and are more likely to develop intractable seizures both preoperatively and postoperatively. The study also found a trend towards higher seizure incidence preoperatively in LGG patients with IDH mutation.
NEURO-ONCOLOGY PRACTICE
(2021)